个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Association between deep prostate-specific antigen decline and survival in patients with high-volume metastatic hormone-sensitive prostate cancer treated with rezvilutamide in the CHART trial

| 导出 | |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE ◇ CPCI(ISTP)

作者：
Chang, K.[1] * ; Zhang, X.[2] ; Xie, L.[3] ; Wang, S.[4] ; Shi, B.[5] ; Sun, T.[6] ; Wei, S.[7] ; Weng, Z.[8] ; Xia, S.[9] ; Han, B.[9] ; Xu, Z.[10] ; Xing, J.[11] ; Zhang, D.[12] ; Xu, D.[13] ; Du, C.[14] ; He, C.[15] ; Wang, Q.[16] ; Lian, J.[17] ; Shi, Q.[17] ; Ye, D.[1] ;
单位： [1]Fudan Univ Shanghai Canc Ctr, Dept Urol, Shanghai, Peoples R China [2]First Affiliated Hosp Zhengzhou Univ, Dept Urol, Zhengzhou, Peoples R China [3]Zhejiang Univ Sch Med, First Affiliated Hosp, Dept Urol, Hangzhou, Peoples R China [4]Huazhong Univ Sci & Technol,Tongji Hosp,Tongji Med Coll,Dept Urol,Wuhan,Peoples R China [5]Qilu Hosp Shandong Univ, Dept Urol, Jinan, Peoples R China [6]First Affiliated Hosp Nanchang Univ, Dept Urol, Nanchang, Jiangxi, Peoples R China [7]Hubei Canc Hosp HBCH, Dept Urol, Wuhan, Hubei, Peoples R China [8]First Affiliated Hosp Wenzhou Med Univ, Dept Urol, Wenzhou, Peoples R China [9]Shanghai Gen Hosp, Urol Med Ctr, Shanghai, Peoples R China [10]Wuxi Peoples Hosp, Dept Urol, Wuxi, Jiangsu, Peoples R China [11]First Affiliated Hosp Xiamen Univ, Dept Urol, Xiamen, Peoples R China [12]Zhejiang Prov Peoples Hosp, Dept Urol, Hangzhou, Peoples R China [13]Shanghai Jiaotong Univ Sch Med, Ruijin Hosp, Dept Urol, Shanghai, Peoples R China [14]Zhejiang Univ Sch Med, Affiliated Hosp 2, Dept Urol, Hangzhou, Peoples R China [15]Henan Cacer Hosp, Dept Urol, Zhengzhou, Peoples R China [16]Third Affiliated Hosp Kunming Med Univ, Yunnan Canc Hosp, Dept Urol, Kunming, Yunnan, Peoples R China [17]Jiangsu Hengrui Pharmaceut Co Ltd, Clin Res & Dev, Shanghai, Peoples R China
出处：
DOI： 10.1016/j.annonc.2023.09.2738
ISSN：
基金：
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
语种：
外文
被引次数：
WOS：
中科院(CAS)分区：
出版当年[2022]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
最新[2025]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
JCR分区：
出版当年[2021]版：
Q1 ONCOLOGY
最新[2023]版：
Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者：
第一作者单位： [1]Fudan Univ Shanghai Canc Ctr, Dept Urol, Shanghai, Peoples R China
推荐引用方式(GB/T 7714)：
Chang K.,Zhang X.,Xie L.,et al.Association between deep prostate-specific antigen decline and survival in patients with high-volume metastatic hormone-sensitive prostate cancer treated with rezvilutamide in the CHART trial[J].ANNALS OF ONCOLOGY.2023,34:S966-S967.doi:10.1016/j.annonc.2023.09.2738.
APA：
Chang, K.,Zhang, X.,Xie, L.,Wang, S.,Shi, B....&Ye, D..(2023).Association between deep prostate-specific antigen decline and survival in patients with high-volume metastatic hormone-sensitive prostate cancer treated with rezvilutamide in the CHART trial.ANNALS OF ONCOLOGY,34,
MLA：
Chang, K.,et al."Association between deep prostate-specific antigen decline and survival in patients with high-volume metastatic hormone-sensitive prostate cancer treated with rezvilutamide in the CHART trial".ANNALS OF ONCOLOGY 34.(2023):S966-S967

资源点击量：426 今日访问量：0 总访问量：410 更新日期：2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有：重庆聚合科技有限公司 渝ICP备12007440号-3 地址：重庆市两江新区泰山大道西段8号坤恩国际商务中心16层（401121）